ArticleClinical endocrinology2025
Congenital Hypothyroidism: Long-Term Growth and Intellectual Outcomes With a Lower Initial Levothyroxine Dose.
Article in Clinical endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesThis study aims to review the long-term outcome of congenital hypothyroidism (CH) and whether patient- or treatment-related factors impact the outcomes, especially focusing on the initial Levothyroxine dose.
methodsThis is a retrospective, cross-sectional study of the children diagnosed with CH who received Levothyroxine at Ajou University Hospital between 2003 and 2024. Comparative analysis was performed between the low (<10 mcg/kg) and high (≥10 mcg/kg) initial dose groups. Repeated-measures analysis of covariance was employed to evaluate longitudinal changes in growth outcomes, and multivariate linear regression was utilised to evaluate the effects of clinical factors on the intelligence quotient (IQ).
resultsAmong the study population, 84 of 144 children were prescribed an initial low dose of Levothyroxine. Most children in both initial dose groups showed appropriate growth within the normal range in the biennial growth evaluation from ages four to eight and in the Wechsler IQ exam. The initial dose seemed to not significantly affect the growth outcomes over time, as no significant differences between the low- and high-dose groups were observed (p values: 0.545, 0.609, 0.532, and 0.501 for bone age-chronological age, height z-score, weight z-score, and BMI z-score, respectively). The effect of the initial dose group on the full-scale IQ was also not statistically significant (p = 0.362).
conclusionWe demonstrated the favourable long-term outcomes in linear growth and neurodevelopment among children with CH, even in lower initial Levothyroxine doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.